Eli Lilly and Novo Nordisk - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

Hosted on MSN · 17h

Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

The New York Times · 10h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.

Wegovy sales double to boost Novo Nordisk's 4th quarter

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

Business Insider · 18h

NVO Earnings: Novo Nordisk Jumps on Healthy Sales Beat Driven by Wegovy

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales

U.S. News & World Report · 23h

Novo Nordisk Q4 Profit Beats Expectations, Sees Slower Growth in 2025

LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen investor concerns that the company is losing its edge in the competitive obesity market to rival Eli Lilly.

10hon MSN

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

21h

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

19h

Novo Nordisk Outlook Provides Some Welcome Relief

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

2don MSN

3 Magnificent Stocks to Buy and Hold Forever

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

2don MSN

What Analysts Think of Eli Lilly Stock Ahead of Earnings

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results